Osteogenesis Imperfecta: update on Pathophysiology and Treatment

March 21, 2012

12:00 – 1:00 PM

Translational Research Center 12-146

Francis H. Glorieux, OC, MD, PhD
Professor Surgery, Pediatrics and Human Genetics at McGill University

Target Audience

This program has been designed for endocrinology, pathology and pediatric endocrine faculty and fellows.

Educational Objectives

After completing this activity, participants should be able to:

·  Describe the most appropriate and newest diagnostic modalities for endocrine diseases

·  Evaluate the efficacy of therapeutic options in endocrine disorders

·  Describe the results of translational research as it pertains to endocrine diseases discussed

Accreditation

The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support*

NONE

For more information, please contact

Sherard Graham

215-746-6391

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania and the peer reviewer(s) Zalman Agus, MD, Associate Dean for CME, have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity.

The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:

Faculty Name

Susan J. Mandel, MD, MPH

Kolin Hoff, MD

Mark Schutta, mD

Presenter Name

The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity.

Faculty Name Name of Commercial Interest Relationship

Anne R. Cappola, MD, ScM Orexigen & Watermark Research Partners Consulting Fee

Presenter Name Name of Commercial Interest Relationship

Francis H. Glorieux, OC, MD, PhD Novartis Consulting Fee (DMC member)

Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected

Disclosure of Unapproved Uses of Products

Presenter name Product Investigational and/or Off-label Use

Frances H. Glorieux, OC, MD, PhD Aredia (pamidronate) treatment of OI

Aclasta (zoledronic acid) treatment of OI